We like to keep you abreast of various regulatory matters involving the FDA. we thought this was an interesting case.
The U.S. Food and Drug Administration (FDA) is providing an important update on the Food and Drug Administration (FDA) and its partner agencies have recently announced charges against Bien King and Khalil King, the operators of “Little City Dogs,” based in New York City. The charges include conspiracy, distribution of unregistered and misbranded pesticides, and interstate shipment of misbranded animal drugs.
The indictment alleges that Bien King and Khalil King purchased unapproved animal drugs and pesticides, such as ivermectin, nitenpyram, praziquantel, and fipronil, from various Chinese suppliers. These suppliers routinely mislabeled the shipments to evade inspection by United States Customs and Border Protection inspectors. Upon receiving these shipments from China, the defendants used multiple locations, including a Manhattan office, to mix and repackage these drugs and pesticides for resale to customers throughout the United States. The indictment further states that their company received over $4,000,000 from the sale of these misbranded, unregistered, and unapproved pesticides and animal drugs.
If convicted, the defendants could face severe penalties, including a maximum possible sentence of 19 years in prison, up to 3 years of supervised release, a $1,450,000 fine, and a $550 special assessment.
This case was meticulously investigated by the Food and Drug Administration’s Office of Criminal Investigations and the Environmental Protection Agency’s Office of Criminal Investigations. It is currently being prosecuted by Assistant United States Attorney Christopher E. Parisi.
It is crucial to remember that an indictment, information, or criminal complaint is an accusation. A defendant is presumed innocent unless and until proven guilty in a court of law.
For more information on this case and FDA’s ongoing efforts to ensure the safety and efficacy of products in the marketplace.
For more information on the FDA’s regulatory activities of explaining this case please contact mdi at: firstname.lastname@example.org and RE: FDA regulatory cases